Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | NFE2L2 | Q16236 | 8/20 | 0.40 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.37 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7603249 | 0.85 | ALDH1A1 (0.55) | CYP3A4TSHRALDH1A1TDP1HSD17B10 | |
| SCHEMBL845336 | 0.80 | CYP3A4 (0.43) | CYP3A4TSHRALDH1A1NFE2L2GAA | |
| SCHEMBL9179403 | 0.80 | TSHR (0.43) | CYP3A4TSHRALDH1A1NFE2L2TXNRD1 | |
| SCHEMBL6501463 | 0.80 | CYP3A4 (0.43) | CYP3A4TSHRALDH1A1NFE2L2SLC40A1 | |
| SCHEMBL1573955 | 0.79 | TSHR (0.48) | CYP3A4TSHRALDH1A1TDP1HSD17B10 | |
| SCHEMBL9174597 | 0.78 | TSHR (0.42) | CYP3A4TSHRALDH1A1NFE2L2TXNRD1 | |
| Potassium Ion SCHEMBL9175274 | 0.78 | NFE2L2 (0.44) | CYP3A4TSHRALDH1A1NFE2L2SLC40A1 | |
| SCHEMBL9174593 | 0.78 | NFE2L2 (0.44) | CYP3A4TSHRALDH1A1NFE2L2SLC40A1 | |
| Lithium Ion SCHEMBL9176164 | 0.78 | NFE2L2 (0.44) | CYP3A4TSHRALDH1A1NFE2L2SLC40A1 | |
| SCHEMBL9176772 | 0.78 | TSHR (0.42) | CYP3A4TSHRALDH1A1NFE2L2TXNRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119143705-A | Benzofuran lymph specific tyrosine phosphatase inhibitor and preparation method and application thereof | 山东大学 | 2024-12-17 | — | — | CN | claimed |
| US-12583824-B2 | 6-membered heteroarylaminosulfonamides for treating diseases and conditions mediated by deficient CFTR activity | GENZYME CORPORATION (US) | 2026-03-24 | — | — | US | disclosed |
| CN-119143705-A | Benzofuran lymph specific tyrosine phosphatase inhibitor and preparation method and application thereof | 山东大学 | 2024-12-17 | — | — | CN | disclosed |
| US-20230137585-A1 | 6-MEMBERED HETEROARYLAMINOSULFONAMIDES FOR TREATING DISEASES AND CONDITIONS MEDIATED BY DEFICIENT CFTR ACTIVITY | GENZYME CORPORATION | 2023-05-04 | — | — | US | disclosed |
| EP-4058434-A1 | 6-MEMBERED HETEROARYLAMINOSULFONAMIDES FOR TREATING DISEASES AND CONDITIONS MEDIATED BY DEFICIENT CFTR ACTIVITY | Genzyme Corporation (US) | 2022-09-21 | — | — | EP | disclosed |
| CN-114981243-A | 6-membered heteroarylaminosulfonamides for treating diseases and conditions mediated by deficiency of CFTR activity | 健赞公司 | 2022-08-30 | — | — | CN | disclosed |
| WO-2021097054-A1 | 6-MEMBERED HETEROARYLAMINOSULFONAMIDES FOR TREATING DISEASES AND CONDITIONS MEDIATED BY DEFICIENT CFTR ACTIVITY | GENZYME CORPORATION (US) | 2021-05-20 | — | — | WO | disclosed |
| EP-3312172-B1 | AMINOPYRAZOLE DERIVATIVES USEFUL AS SRC KINASE INHIBITORS | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2020-05-06 | — | — | EP | disclosed |
| US-10479780-B2 | Aminopyrazole derivatives | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2019-11-19 | — | — | US | disclosed |
| EP-3312172-A1 | AMINOPYRAZOLE DERIVATIVES | Chugai Seiyaku Kabushiki Kaisha (JP) | 2018-04-25 | — | — | EP | disclosed |
| EP-1814849-B1 | HETEROCYCLIC COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR | ABBOTT GMBH & CO KG (DE) | 2011-04-06 | — | — | EP | disclosed |
| EP-2271625-A2 | TETRAHYDROISOQUINOLINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | Abbott GmbH & Co. KG (DE) | 2011-01-12 | — | — | EP | disclosed |
| US-7851463-B2 | Heterocyclic compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor | ABBOTT GMBH & CO. KG (DE) | 2010-12-14 | — | — | US | disclosed |
| WO-2009121872-A2 | TETRAHYDROISOQUINOLINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBOTT GMBH & CO. KG (DE) | 2009-10-08 | — | — | WO | disclosed |
| US-20090247746-A1 | Fused heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-01 | — | — | US | disclosed |
| US-20080045493-A1 | Heterocyclic Compounds Suitable For Treating Disorders That Respond To Modulation Of The Dopamine D3 Receptor | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2008-02-21 | — | — | US | disclosed |
| EP-1873144-A1 | FUSED HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2008-01-02 | — | — | EP | disclosed |
| CN-101039904-A | Is suitable for treating dopamine D3Heterocyclic compounds for receptor-modulated responsive disorders | ABBOTT GMBH & CO KG (DE) | 2007-09-19 | — | — | CN | disclosed |
| EP-1814849-A1 | HETEROCYCLIC COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR | Abbott GmbH & Co. KG (DE) | 2007-08-08 | — | — | EP | disclosed |
| WO-2006040182-A1 | HETEROCYCLIC COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR | ABBOTT GMBH & CO. KG (DE) | 2006-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247746-A1 | Fused heterocyclic compound | GCKR, GCK, GPR119 | CYP3A4 336/4885TSHR 3701/4885ALDH1A1 372/4885 |
| US-10479780-B2 | Aminopyrazole derivatives | SRC, GRK2, GRK3 | CYP3A4 1253/4885TSHR 3197/4885ALDH1A1 1534/4885 |
| US-12583824-B2 | 6-membered heteroarylaminosulfonamides for treating diseases and conditions mediated by deficient CFTR activity | CFTR, CLIC1, NHERF1 | CYP3A4 1612/4885TSHR 796/4885ALDH1A1 804/4885 |
| US-20230137585-A1 | 6-MEMBERED HETEROARYLAMINOSULFONAMIDES FOR TREATING DISEASES AND CONDITIONS MEDIATED BY DEFICIENT CFTR ACTIVITY | CFTR, PKD2, PKD1 | CYP3A4 1651/4885TSHR 3772/4885ALDH1A1 2014/4885 |
| US-20080045493-A1 | Heterocyclic Compounds Suitable For Treating Disorders That Respond To Modulation Of The Dopamine D3 Receptor | DRD3, MC3R, CHRNA3 | CYP3A4 1322/4885TSHR 38/4885ALDH1A1 1263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.